- Home
- ADAG vs EIC Comparison
ADAG vs EIC Comparison
Compare ADAG & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADAG | EIC |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.3M | 228.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADAG | EIC |
|---|---|---|
| Price | $4.47 | $10.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.25 | ★ $12.63 |
| AVG Volume (30 Days) | ★ 270.7K | 77.8K |
| Earning Date | 04-01-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 13.25% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.44 | $9.17 |
| 52 Week High | $4.85 | $13.92 |
Technical Indicators
Market Signals| Indicator | ADAG | EIC |
|---|---|---|
| Relative Strength Index (RSI) | 62.38 | 49.76 |
| Support Level | $3.21 | $9.83 |
| Resistance Level | $4.66 | $11.34 |
| Average True Range (ATR) | 0.45 | 0.15 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 75.46 | 76.68 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.